TikoMed

Executive Summary

TikoMed AB is a privately held Swedish biotech company founded in 2005, based in Västra Frölunda. The company focuses on developing ILB®, a novel small molecule designed to stimulate the body's innate repair mechanisms, primarily targeting neurodegenerative and other progressive diseases. Through its proprietary platform, TikoMed aims to address significant unmet medical needs by promoting endogenous regeneration and neuroprotection. The company operates via a subsidiary model, where drug candidates are developed within separate entities before being advanced toward clinical validation.

Upcoming Catalysts (preview)

• H2 2027Phase 2 clinical data readout for lead indication (e.g., multiple sclerosis or ALS)40% success
• H1 2027Orphan Drug Designation from FDA for a lead program60% success
• Q4 2026Partnership or licensing deal with a larger biopharma30% success